Tech-enabled, next-generation contract research organisation (CRO) Vial has announced a partnership to integrate Egnyte’s Life Sciences electronic trial master file (eTMF) solution into its clinical trial platform. Egnyte eTMF minimises document processing times and maintains […]
OIn 2022, 54% of FDA new drug approvals were for rare diseases, a significant increase in proportion of approvals in the recent years. At the town hall, Dr. Melanie Blank, a primary reviewer at the […]
Storm Therapeutics has received a Biomedical Catalyst grant from Innovate UK for carrying out research and development of new therapies against a SARS-CoV-2 protein. For drug development, the company will leverage its ribonucleic acid (RNA) […]
The European Commission (EC) has granted approval for Horizon Therapeutics’ Uplizna (inebilizumab) as monotherapy to treat neuromyelitis optica spectrum disorder (NMOSD) in adults. The treatment is intended for NMOSD patients who are anti-aquaporin-4 immunoglobulin G […]
The European Commission (EC) has updated the marketing authorization for Sanofi and Regeneron’s Dupixent (adupilumab) to include as an add-on maintenance treatment for severe asthma with type 2 inflammation in children of the age six […]